These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36703785)

  • 41. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report.
    Damásio I; Simões-Pereira J; Donato S; Horta M; Cavaco BM; Rito M; Gomes P; Leite V
    Eur Thyroid J; 2023 Feb; 12(1):. PubMed ID: 36378538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
    Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
    Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With
    Dunn DB
    J Adv Pract Oncol; 2020; 11(4):418-423. PubMed ID: 33604102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
    Xiang S; Lu X
    Acta Pharm Sin B; 2024 Feb; 14(2):517-532. PubMed ID: 38322338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of
    Liu D; Offin M; Harnicar S; Li BT; Drilon A
    Ther Clin Risk Manag; 2018; 14():1247-1252. PubMed ID: 30050303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
    Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
    Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
    Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
    Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
    Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 52. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TRK inhibitor in a patient with metastatic triple-negative breast cancer and
    Medford AJ; Oshry L; Boyraz B; Kiedrowski L; Menshikova S; Butusova A; Dai CS; Gogakos T; Keenan JC; Occhiogrosso RH; Ryan P; Lennerz JK; Spring LM; Moy B; Ellisen LW; Bardia A
    Ther Adv Med Oncol; 2023; 15():17588359231152844. PubMed ID: 36743521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
    Hanf D; Heining C; Laaber K; Nebelung H; Uhrig S; Hutter B; Jahn A; Richter D; Aust D; Herbst F; Fröhling S; Glimm H; Folprecht G
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250401
    [No Abstract]   [Full Text] [Related]  

  • 56. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated
    Mayr L; Guntner AS; Madlener S; Schmook MT; Peyrl A; Azizi AA; Dieckmann K; Reisinger D; Stepien NM; Schramm K; Laemmerer A; Jones DTW; Ecker J; Sahm F; Milde T; Pajtler KW; Blattner-Johnson M; Strbac M; Dorfer C; Czech T; Kirchhofer D; Gabler L; Berger W; Haberler C; Müllauer L; Buchberger W; Slavc I; Lötsch-Gojo D; Gojo J
    J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33353026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathological features of two cases of
    Ke J; Cao M; Zhang W; Huang H; Chen P; Liu J; Shan D; Ke J; Wang Z; Liu J; Li Y; Xiao S
    Front Oncol; 2024; 14():1332522. PubMed ID: 38863624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.